Loading...
NPI 1982360004 · Escondido, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Empower Genomics Corp is a clinical medical laboratory provider located in Escondido, California. This profile covers 7 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Empower Genomics Corp |
| Address | 600 La Terraza Blvd |
| City | Escondido |
| State | CA |
| ZIP | 92025 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 12, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $6.5M |
| Medicaid | $252.2K |
EMPOWER GENOMICS CORP’s billing pattern is overwhelmingly concentrated in COVID-19 testing services, with K1034 (provision of nonprescription self-administered COVID-19 tests) alone representing $6.4M of the provider’s Medicare revenue and accounting for the vast majority of its activity under that payer. The provider’s top three Medicare codes together account for 99.0% of total Medicare revenue, signaling an operational focus on a narrow set of, pandemic-era testing services rather than a broad clinical laboratory portfolio.
On Medicare the single code K1034 is an extreme outlier nationally: the provider reported 532.4K claims and $6.4M revenue for K1034 and ranks #76 of 30143 providers (100th percentile; extreme outlier). Other Medicare codes tied to SARS‑CoV‑2 testing such as U0003 ($82.3K) and G2023 ($44K) contribute far smaller shares individually, reinforcing that Medicare dominance stems almost entirely from K1034.
Although K1034 dominates Medicare, the provider also shows above‑typical volume for other testing codes at the national level; for example, 87426 generated $31.8K on Medicare and ranks #28 of 17750 providers (100th percentile; notably above typical national volume). These secondary high-percentile ranks indicate the lab also performs immunoassay‑based antigen testing at volumes exceeding many peers, even if those codes are small compared with K1034.
On Medicaid the revenue mix is similarly concentrated but more evenly split across three COVID-related codes: U0003 ($81.5K, 32.5% of Medicaid revenue), 87426 ($80.9K, 32.2%), and G2023 ($72.3K, 28.8%). The top three Medicaid codes together account for 93.5% of the provider’s total Medicaid revenue, showing the same narrow service‑line dependence on SARS‑CoV‑2 testing and specimen collection in the state payer mix.
State-level competitive standing on Medicaid is modest to solid but not dominant: the provider’s in‑state ranks for its top Medicaid codes are largely in the mid percentiles (U0003 ranks #339 of 751, 55th percentile; 87426 ranks #144 of 821, 83th percentile; G2023 ranks #130 of 497, 74th percentile). This pattern suggests EMPOWER GENOMICS competes as a typical to above‑typical state participant for lab testing services rather than being a clear statewide leader.
The provider’s overall payer mix is strongly skewed toward Medicare in scale: lifetime Medicare revenue is $6.5M versus lifetime Medicaid revenue of $252.2K, indicating Medicare is the dominant source of reported public payer revenue. With Medicaid revenue a small fraction of Medicare, the entity functions effectively as a Medicare‑scale operation in terms of public reimbursement.
EMPOWER GENOMICS was enumerated with an NPI on 2021-11-12 (~5 years ago), making it a relatively recent entrant in the public datasets; despite that tenure it has rapidly accumulated substantial Medicare billing on K1034. This short operating history combined with very high volumes for pandemic-era testing codes suggests rapid scale-up focused on COVID testing channels.
The extreme concentration of revenue within a few COVID‑related codes (99.0% of Medicare and 93.5% of Medicaid revenue coming from the top three codes) implies limited service diversification and potential sensitivity to shifts in public demand or reimbursement for SARS‑CoV‑2 testing. For payers and network analysts, this profile points to a specialized laboratory relationship driven by high-volume test provision rather than a broad diagnostic services partnership.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 532,370 | $10 | $6.4M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,110 | $70 | $82.3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,910 | $20 | $44K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 910 | $40 | $31.8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,110 | $30 | $27.8K |
| 87804 | The analyst performs an immunoassay with direct optical, meaning visual, observation to detect influenza, also called flu, in a patient sample, typically a throat or nasal swab or nasal washings. | 260 | $20 | $4.1K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 40 | $50 | $1.8K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 7 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,250 | $70 | $81.5K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 2,890 | $30 | $80.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3,440 | $20 | $72.3K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 210 | $40 | $8.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 210 | $20 | $4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,030 | $1 | $2.1K |
| 87804 | The analyst performs an immunoassay with direct optical, meaning visual, observation to detect influenza, also called flu, in a patient sample, typically a throat or nasal swab or nasal washings. | 200 | $10 | $1.6K |
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 339 | 750 | 950 | $50 | $890K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 130 | 500 | 530 | $20 | $128.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 321 | 520 | 470 | $10 | $116K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 751 | 1,210 | 420 | $30 | $95.7K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 144 | 820 | 290 | $20 | $40.7K |
| 87804 | The analyst performs an immunoassay with direct optical, meaning visual, observation to detect influenza, also called flu, in a patient sample, typically a throat or nasal swab or nasal washings. | 579 | 1,090 | 250 | $10 | $6.9K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 12 | 50 | 120 | $1 | $3.4K |
Other providers in the same ZIP code as Empower Genomics Corp, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Neighborhood Healthcare | CA | Federally Qualified Health Center (FQHC) | $0 | $125M |
| Neighborhood Healthcare | CA | Federally Qualified Health Center (FQHC) | $0 | $38.3M |
| Dap Health, Inc. | CA | Federally Qualified Health Center (FQHC) | $0 | $28.6M |
| Escondido Ca Endoscopy Asc LP | CA | Ambulatory Surgical Clinic/Center | $499.2K | $5.2M |
| Amar Amin | CA | Diagnostic Radiology Physician | $3.6M | $6.5K |
| Joshua Morrison-reyes | CA | Retina Specialist (Ophthalmology) Physician | $2M | $18.2K |
| Debra Hexom | CA | Family Nurse Practitioner | $1.8M | $0 |
| Philip Bosch | CA | Urology Physician | $1.3M | $230 |
| Mission Treatment Services, Inc. | CA | Methadone Clinic | $167.7K | $683.8K |
| Veni-express, Inc. | CA | Clinical Medical Laboratory | $487.1K | $221.9K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.